We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Attorney Mistake Dooms Angiomax Patent Extension

Law360 (December 11, 2006, 12:00 AM EST) -- The Medicines Co. disclosed Monday that the U.S. Patent and Trademark Office has rejected its application to extend its patent on the blood thinning drug Angiomax.

In papers filed with the Securities and Exchange Commission, the Medicines Co. blamed its attorneys, saying the application was shot down because its counsel did not hand it in on time.

The patent for Angiomax currently expires in 2010, but the Parsippany, N.J.-based pharmaceutical company was hoping to push the expiration date forward to 2014.

In February 2001, lawyers for...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.